48
Participants
Start Date
February 29, 2024
Primary Completion Date
January 23, 2025
Study Completion Date
January 23, 2025
Trelegy Ellipta 100/62.5/25Mcg Inh 30D
Product to be used according to specifications. 1 inhalation daily for 12 months
Brimica
As per product specifications
Duaklir
As per product specifications
Ultibro
As per product specifications
Ulunar
As per product specifications
Xoterna
As per product specifications
Anoro
As per product specifications
Laventair
As per product specifications
Spiolto Respimat
As per product specifications
Yanimo
As per product specifications
Foradil
As per product specifications
Broncoral
As per product specifications
Formoterol stada
As per product specifications
Oxis
As per product specifications
Formatris
As per product specifications
Formoterol Aldo
As per product specifications
Onbrez
As per product specifications
Oslif
As per product specifications
Hirobriz
As per product specifications
Striverdi
As per product specifications
Beglan
As per product specifications
Betamican
As per product specifications
Inaspir
As per product specifications
Serevent
As per product specifications
Soltel
As per product specifications
Eklira
As per product specifications
Bretaris
As per product specifications
Seebri
As per product specifications
Tovanor
As per product specifications
Enurev
As per product specifications
Spiriva
As per product specifications
Tavulus
As per product specifications
Sirkava
As per product specifications
Braltus
As per product specifications
Gregal
As per product specifications
Incruse
As per product specifications
Rolufta
As per product specifications
Hospital Clínic Barcelona, Barcelona
Collaborators (1)
GlaxoSmithKline
INDUSTRY
Fundacio Privada Mon Clinic Barcelona
OTHER